ABSTRACT
Objective To evaluate the efficacy of seretide (fluticasone/salmeterol) in treatment of patients with cough variant asthma(CVA). Methods 86 CVA patients were treated with fluticasone/salmeterol propionate 8 weeks, after 8 weeks, 86 patients were randomly assigned to treatment group and control group, each group with 43 patients, the treatment group continued medicine for 4 weeks, the control group without any treatment.The two groups of patients FENO measurement values, cough symptom score before treatment and after treatment for 8 weeks, 12 weeks were compared. Results After treatment for 8 weeks, cough symptom scores and FeNO in the two groups values decreased significantly compared with those before treatment(P<0.05), 12 weeks after treatment, treatment group cough product, FeNO values, were lower than in control group(P<0.05).Conclusion Fluticasone salmeterol powder inhalation can effectively improve the symptoms of cough cough variant asthma.Symptom score and FENO value can be used as a monitoring index to evaluate the therapeutic effect of CVA, and the FENO value is more effective, which has the advantages of non-invasive, simple, safe, rapid and repeatable.
ABSTRACT
OBJECTIVE:To review economics of budesonide/formoterol and fluticasone/salmeterol for asthma systematically, and to provide evidence-based basis for rational selection of drug to treat asthma. METHODS:Retrieved from Medline,EMBase, EBM reviews (HTA,NHSEED),CBM,CJFD,Wanfang database,researches about pharmacoeconomics of budesonide/formoterol (test group) versus fluticasone/salmeterol (control group)for asthma were collected,and analyzed with qualitative systematic re-view method. RESULTS:A total of 7 researches and 13 comparative data were included,containing 6 682 patients. The incidence of severe acute asthma of test group were lower than those of control group,with significant difference(P<0.05). The total costs and direct costs of test group were lower than those of control group. Good effect had been achieved in test group with low cost. CONCLUSIONS:Budesonide/formoterol is more cost-effective than fluticasone/salmeterol in teenagers patients and adults who fail to control asthma. Due to limitation of included studies,large-scale and high-quality studies are required for further validation of the conclusion.
ABSTRACT
Objective To compare the clinical efficacy of seretide (50 μg/500 μg salmeterol/fluticasone propionate) with seretide (50 μg/250 μg salmeterol/fluticasone propionate) in single inhaler in the treatment of patients with stable status moderate to severe chronic obstructive pulmonary disease (COPD)Methods Sixty patients with COPD were randomly divided into the treatment and the control groups.Baseline treatments were similar in all patients,patients in the treatment group received seretide (50 μg/500 μg) while the control group received seretide (50 μg/250 μg) inhalation once every 12 hours for 24 weeks Before and after the therapeutic course,tests for lung function in patients of the two groups were conducted and compared with each other.Clinical symptoms and physical signs were graded by questionnaire.Results There was no significant difference on indexes of lung function between the two groups at baseline (P ＞ 0.05).After treatment,the score of clinical symptoms and signs in the treatment group was lower than that in the control group ((4.0 ± 0.5) vs.(4.8 ± 0.3),t =2.63,P ＜ 0.05).Six minutes walking distance was longer in the treatment group than that in the control group ((451.6±22.9) meter vs.(401.2 ±25.4) meter,t =2.51,P ＜0.05).The levels of forced exhaled gas volume 1 (FEV1),FEV1/forced vital capacity (FVC) and FEV1/pred in the treatment group were higher than those in the control group ([FEV1:(2.18 ± 0.38) L vs.(1.78 ± 0.45) L;FEV1/pred:(63.19 ±9.08)％ vs.(57.19 ±9.25)％; FEV1/FVC％:(73.8 ±5.6)％ vs.(67.3 ± 11.5)％ ;P ＜ 0.05).Conclnsion High dosage of seretide had better effect in the treatment of stable moderate and severe COPD,and can obviously improve patients' lung function,clinical symptoms and quality of life.